GTBP News and Press, GT Biopharma Inc. From 09/08/22

BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that...

GTB-3650’s IND application with the FDA expected by end of first quarter of 2023 BRISBANE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on dev...

GT Biopharma press release ( NASDAQ: GTBP ): Q2 GAAP EPS of -$0.10 beats by $0.07 . The Company had total cash, cash equivalents and short-term investments of $23.7 million as of June 30, 2022, compared to $32.0 million as of December 31, 2021. This is expected to prov...

Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE ® ) driving robust NK cell function against B cell malignancies at EHA 2022 Congress. GTB-5550 (B7-H3) abstract poster presentation accepted at upcoming ESMO 2022 Cong...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivo Future studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the...

GT Biopharma press release (NASDAQ:GTBP): Q1 GAAP EPS of -$0.17. The Company had total cash, cash equivalents and short-term investments of $26.7M as of Mar. 31. Shares were trading +1.04% pre-market. For further details see: GT Biopharma GAAP EPS of -$0.17

Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE ® ) driving NK cell activation and ADCC against head and neck squamous cell carcinomas GT Biopharma to partici...

BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE ® protein biologic technology platf...

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo - Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor microenvironment BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (&...